Picture of Abivax SA logo

ABVX — Abivax SA News Story

0.000.00%
fr flag iconLast trade - 00:00
HealthcareHighly SpeculativeLarge CapSucker Stock

France has had no request for investment approval in biotech Abivax - official (updated)

Adds background, comment from French official in paragraphs 2-4

PARIS, Jan 12 (Reuters) - France's finance ministry has received no request seeking investment approval in French biotech Abivax and has had no contact with Eli Lilly, a ministry official said on Monday, after a media report that the U.S. pharma giant was still interested in buying the company.

Shares in Abivax ABVX.PA soared up to 23%, exceeding 121 euros, earlier on Monday after French media La Lettre reported that Eli Lilly LLY.N was ready to buy biotech for 15 billion euros ($17.5 billion), almost double its current market capitalisation.

Shortly before 0300 GMT, shares were still gaining around 8%.

Any move by Eli Lilly would be subject to a mandatory screening by the French finance ministry, the official said.

 (Reporting by Mathieu Rosemain, writing by Louise Rasmussen, editing by Benoit Van Overstraeten)

 ((Louisebreusch.rasmussen@tr.com; +45 21 27 97 79;))

Recent news on Abivax SA

See all news